Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Guanfacine for drug craving and use in women with SUD
NCT03980184Phase 2Completed
- Sponsor
- Yale University
- Start
- Nov 2019
- Primary completion
- Nov 2022
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of guanfacine in substance use disorder (SUD), sponsored by Yale University. Primary endpoint: Change in Drug Use With Substance Use Calendar at 10 weeks. Started Nov 2019; status: completed.
02
Drugs
guanfacine
03
Conditions
substance use disorder (SUD)
Beyond the preview
Go deeper on NCT03980184.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03980184.